Friedman Billings Cuts Lilly to 'Market Perform'

Analyst David Moskowitz sees several risks ahead for the drug giant, including drug launch delays and higher marketing costs

Friedman Billings downgraded Eli Lilly (LLY ) to market perform from outperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.